A CRISPR-based treatment to stop the replication of both the flu virus and the virus that causes COVID-19 in mice. Moreover, the new treatment is delivered to the lungs via a nebulizer, which could make it simple for patients to administer themselves at home.
The treatment uses a type of CRISPR to target viral RNA and appears to stop replication of both viruses in the lungs.
Comments are closed.